Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.

ABSTRACT:

Aims

To investigate the differences in clinical outcomes and costs for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) with a combined positive score (CPS) of 1-19, with pembrolizumab ± chemotherapy or a cetuximab-containing regimen (CCR) in Italy.

Methods

A naïve indirect treatment comparison was conducted, and outcomes were incorporated into a newly developed cost-utility model. Inputs were derived from clinical trials, technology appraisal reports, and published literature. Scenario analyses were undertaken to explore key areas of uncertainty.

Results

Across the comparisons of pembrolizumab ± chemotherapy versus CCRs, incremental life-years ranged from - 0.502 to 0.155, while incremental quality-adjusted life ye

SUBMITTER: Ivanyi P 

PROVIDER: S-EPMC12150647 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature